KDR and neoplasm: A similar anti-angiogenic targeted drug, apatinib, suppressing tumor growth by highly and selectively inhibiting the tyrosine kinase activity of VEGFR-2, was approved by CFDA as early as in 2014 for advanced gastric or esophagogastric junction cancer following disease progression or recurrence after at least two previous systematic chemotherapy regimens (28).